“Your work makes the rest of it work,” NCI Director Bertagnolli says to clinical trialists at ECOG-ACRIN meeting

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

Late next month, NCI is expected to publish the new criteria it uses to bestow designations on America’s network of cancer centers.

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Members of the National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs at a recent meeting struggled to define the new group’s the role and raised concerns about some initial growing pains.

Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus

Dinah S. Singer is now an NIH Scientist Emeritus after retiring from NCI in June.

October 30, 2026

Vol.52 No.40

In Brief

University of Illinois’ Andrei Gartel receives NCI grant to study AML

NCI awarded a two-year $422,000 grant to University of Illinois Cancer Center member Andrei Gartel to examine what might influence differences in outcomes for some patients with acute myeloid leukemia, an aggressive blood cancer with persistently poor outcomes in which relapse is common.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase III open-label, multicenter, randomized DeLLphi-305 study.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors.

October 30, 2026

Vol.52 No.40

“Your work makes the rest of it work,” NCI Director Bertagnolli says to clinical trialists at ECOG-ACRIN meeting

YOU MAY BE INTERESTED IN

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus

University of Illinois’ Andrei Gartel receives NCI grant to study AML

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login

“Your work makes the rest of it work,” NCI Director Bertagnolli says to clinical trialists at ECOG-ACRIN meeting

YOU MAY BE INTERESTED IN

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprisesNew NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus

University of Illinois’ Andrei Gartel receives NCI grant to study AML

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Never miss an issue!

Login

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”